Search - tctmd.com

Displaying 461 - 480 of 491

Sort: Relevancy | Date

Presentation TCT 2012

Does Atrial Fibrillation Ablation Reduce Cardioembolic Stroke?

Presenter: Vivek Reddy

October 24, 2012

Presentation TCT 2012

Case 4: The Patient with Atrial Fibrillation Presenting with an Acute Coronary Syndrome

Presenter: Michael Ezekowitz

October 24, 2012

Presentation TCT 2012

Anticoagulation Choices for Atrial Fibrillation: Which Drug for Which Patient?

Presenter: Michael Ezekowitz

October 24, 2012

Presentation TCT 2012

Strategies for the ACS Patient with Chronic Atrial Fibrillation

Presenter: C. Michael Gibson

October 24, 2012

Presentation TCT 2012

TCT-84. Watchman Left Atrial Appendage Closure in Atrial Fibrillation Patients 75 Years or Greater; A Sub-Analysis of the PROTECT AF Study

Presenter: Saibal Kar

October 23, 2012

Presentation TCT 2012

TCT-83. Watchman Left Atrial Appendage Closure in Atrial Fibrillation Patients with Contraindication to Oral Anticoagulation: the “Aspirin Plavix Registry” (ASAP)

Presenter: Horst Sievert

October 23, 2012

Presentation TCT 2012

Modeling the Risk of Stroke and Bleeding in Atrial Fibrillation: What Are the Optimal Risk Scores?

Presenter: Roxana Mehran

October 23, 2012

Presentation TCT 2012

Atrial Fibrillation:
1. CHADS2 vs. CHA2DS2-VASc Risk Assessment.
2. AHA/ACC vs. ACCP/ESC Approach to Stroke Prevention.

Presenter: Peter Brady

October 23, 2012

Presentation TCT 2012

TCT-62. Impact of Atrial Fibrillation in Patients with STEMI Before and After Primary PCI: Insights from the HORIZONS-AMI Trial

Presenter: A. Rene

October 23, 2012

Presentation TCT 2012

New-Onset Atrial Fibrillation After TAVR: More Frequent than Reported and a Possible Predictor of Stroke

Presenter: Josep Rodes-Cabau

October 22, 2012

Presentation

Efficacy and Safety of the Novel Oral Anticoagulants in A-Fib: A Systematic Review and Meta-Analysis

Presenter: Francesco Dentali

October 18, 2012

Presentation

Percutaneous LAA Suture Ligation Using the LARIAT Device in Patients with A-fib

Presenter: K. Bartus

October 11, 2012

Presentation

Bleeding with Aspirin vs. Apixaban in Patients with A-fib Unsuitable for Warfarin: The AVERROES Trial

Presenter: Greg C. Flaker

October 09, 2012

Presentation

Efficacy and Safety of Apixaban vs. Warfarin Based on Patient Risk of Stroke and Bleeding in A-fib

Presenter: Renato D. Lopes

October 03, 2012

Presentation

Percutaneous LAA Closure for Stroke Prevention in A-fib Patients: An Assessment of Net Clinical Benefit

Presenter: S.R. Gangireddy

September 26, 2012

Presentation

Systemic Review and Adjusted Indirect Comparison Meta-analysis of Oral Anticoagulants in A-fib

Presenter: 89964|William Baker

September 10, 2012

Presentation

Indirect Comparisons of New Oral Anticoagulant Drugs When Used for Stroke Prevention in A-fib

Presenter: GYH Lip

August 13, 2012

Presentation

Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in A-fib Patients Following MI and PCI

Presenter: M. Lamberts

August 10, 2012

Presentation

Does the Left Atrial Appendage Morphology Correlate with Stroke Risk in Patients with A-fib?

Presenter: L. Di Biase

July 30, 2012

Presentation

Oral Anticoagulation Therapy in A-Fib Pts at High Bleeding Risk Undergoing Coronary Artery Stenting

Presenter: 204943|JM Ruiz-Nodar

July 13, 2012

Advertisement

Does Atrial Fibrillation Ablation Reduce Cardioembolic Stroke?

Case 4: The Patient with Atrial Fibrillation Presenting with an Acute Coronary Syndrome

Anticoagulation Choices for Atrial Fibrillation: Which Drug for Which Patient?

Strategies for the ACS Patient with Chronic Atrial Fibrillation

TCT-84. Watchman Left Atrial Appendage Closure in Atrial Fibrillation Patients 75 Years or Greater; A Sub-Analysis of the PROTECT AF Study

TCT-83. Watchman Left Atrial Appendage Closure in Atrial Fibrillation Patients with Contraindication to Oral Anticoagulation: the “Aspirin Plavix Registry” (ASAP)

Modeling the Risk of Stroke and Bleeding in Atrial Fibrillation: What Are the Optimal Risk Scores?

Atrial Fibrillation:
1. CHADS2 vs. CHA2DS2-VASc Risk Assessment.
2. AHA/ACC vs. ACCP/ESC Approach to Stroke Prevention.

TCT-62. Impact of Atrial Fibrillation in Patients with STEMI Before and After Primary PCI: Insights from the HORIZONS-AMI Trial

New-Onset Atrial Fibrillation After TAVR: More Frequent than Reported and a Possible Predictor of Stroke

Efficacy and Safety of the Novel Oral Anticoagulants in A-Fib: A Systematic Review and Meta-Analysis

Percutaneous LAA Suture Ligation Using the LARIAT Device in Patients with A-fib

Bleeding with Aspirin vs. Apixaban in Patients with A-fib Unsuitable for Warfarin: The AVERROES Trial

Efficacy and Safety of Apixaban vs. Warfarin Based on Patient Risk of Stroke and Bleeding in A-fib

Percutaneous LAA Closure for Stroke Prevention in A-fib Patients: An Assessment of Net Clinical Benefit

Systemic Review and Adjusted Indirect Comparison Meta-analysis of Oral Anticoagulants in A-fib

Indirect Comparisons of New Oral Anticoagulant Drugs When Used for Stroke Prevention in A-fib

Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in A-fib Patients Following MI and PCI

Does the Left Atrial Appendage Morphology Correlate with Stroke Risk in Patients with A-fib?

Oral Anticoagulation Therapy in A-Fib Pts at High Bleeding Risk Undergoing Coronary Artery Stenting

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content